Cefiderocol/Xeruborbactam
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Infections
Conditions
Bacterial Infections
Trial Timeline
Sep 16, 2025 → Dec 23, 2026
NCT ID
NCT07104162About Cefiderocol/Xeruborbactam
Cefiderocol/Xeruborbactam is a phase 1 stage product being developed by Shionogi for Bacterial Infections. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07104162. Target conditions include Bacterial Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07104162 | Phase 1 | Recruiting |
Competing Products
20 competing products in Bacterial Infections